CHP
KALV

Cable Hill Partners’s KalVista Pharmaceuticals KALV Stock Holding History

Cable Hill Partners’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,000
Closed -$11K – 917
2017
Q4 		$11K Buy
+1,000
New +$10.4K ﹤0.01% 548

Other funds holding KALV

SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
IBT
International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Cable Hill Partners's KALV Position: Q1 2018 in Review

Cable Hill Partners sold out of KalVista Pharmaceuticals (KALV) in Q1 2018, closing a stake of 1,000 shares — an estimated $11K sold.

Cable Hill Partners first reported a position in KALV in Q4 2017 and held it in 1 quarter. The position peaked at $11K in Q4 2017. 25 funds tracked by Wall St. Rank hold KALV as of Q1 2018.

  • Cable Hill Partners reported no remaining KalVista Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Cable Hill Partners sold 1,000 KalVista Pharmaceuticals shares in Q1 2018, an estimated $11K.
  • Cable Hill Partners first reported a position in KalVista Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Cable Hill Partners's KalVista Pharmaceuticals position peaked at $11K in Q4 2017.
  • 25 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2018.

Based on Cable Hill Partners's 13F filing for Q1 2018, filed 20 Apr 2018.